Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

Fort Lauderdale, FL (May 4, 2009): Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosciences, demonstrate the ability of LX211 (LUVENIQ, voclosporin oral capsule) to significantly improve this chronic eye inflammation. Additionally, in patients who are discontinuing potentially toxic medications for uveitis, such as the corticosteroid prednisone, LX211 actively reduces the rate of inflammatory exacerbations by 50% at six months, compared to placebo. The study results also show a safety profile for LX211 at the 0.4 mg/kg bid dose that suggests the experimental drug would be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory eye disease, while also providing a means to greatly reduce the serious health risks associated with long-term corticosteroid use. LX211 is a novel and proprietary next-generation calcineurin inhibitor that Lux Biosciences is developing for ophthalmic uses.

Dr. James T. Rosenbaum, M.D., Professor of Ophthalmology, Medicine and Cell Biology and Vice-Chair of the Department of Ophthalmology of the Casey Eye Institute Oregon Health Sciences University (OHSU), represented the LUMINATE Investigator Network in presenting the Phase 3 LUMINATE program results for the first time at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The LUMINATE program, consisting of three randomized, double-masked, dose-ranging and placebo-controlled trials that enrolled a total of 558 patients at 56 sites in 7 countries (United States, Canada, United Kingdom, France, Germany, Austria and India), is the largest clinical program ever conducted in uveitis.

"Uveitis, a term used to classify a group of autoimmune diseases characterized by chronic inflammation of
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. The first DFG research centers to be funded for another 4 years
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/28/2015)... ZIONA, Israel , ... Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing ... products, today announced that Shomrat Shurtz has been ... 20, 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... over 25 years of experience in marketing, regulatory ...
(Date:7/27/2015)... Tenn. , July 27, 2015  Capella ... care services and one of the largest for-profit ... its parent company and sole stockholder, Capella Holdings, ... Properties Trust, Inc. ("MPT") (NYSE: MPW ) ... The transaction is expected to be finalized during ...
(Date:7/27/2015)... ... 27, 2015 , ... Production of high tenacity filament yarn of viscose rayon ... EU. For instance, it surpassed the EUR 106 million mark (in value terms) in ... is a major producer, while Italy is a key consumer. , The high ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... A new Oak Ridge National Laboratory initiative could ... and also lead to more information about climate change. ... will be implemented in Gulfport, Miss., Memphis, and Charleston, ... for, respond to and quickly recover from natural and ...
... combining two materials to make a composite material with ... a mainstay of the marine industry for decades and ... carbon nanotubes (CNT) are getting in on the act ... for polymers in an ideal manner. , Researchers ...
... Calif., Nov. 21 Accuray,Incorporated (Nasdaq: ARAY ), ... that its president and chief executive officer, Euan S.,Thomson, ... Piper,Jaffray,s Health Care Conference at the Pierre Hotel in ... p.m. EST (9:30 a.m. PST)., A live webcast ...
Cached Biology Technology:ORNL 'resilience' plan to help Tennessee, Mississippi and South Carolina communities beat disaster 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 3
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... The U.S. Food & Drug Administration (FDA) has granted Investigational ... clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, ... University of the Negev. This is the first time ... AAT is an FDA-approved off-patent drug currently used to treat ...
... The Netherlands believe they are on the verge of ... able to detect accurately chromosomal abnormalities in the developing ... this is through amniocentesis or chorionic villus sampling, both ... triggering a miscarriage. Dr Suzanna Frints, a clinical ...
... wildfires and influxes of pollutants create disturbances that ... Ecologists had believed that at times like these, ... struggle to survive. But a new laboratory ... of acoustic disturbance now challenges that assumption ...
Cached Biology News:FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado 2Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy 2Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy 3Study challenges long-held assumption about competition in disturbed ecosystems 2Study challenges long-held assumption about competition in disturbed ecosystems 3Study challenges long-held assumption about competition in disturbed ecosystems 4
... with a variety of motion options - ... one unit. Shake, rock, roll and rotate ... for hybridization and blotting procedures requiring different ... upper chamber uses a roller action to ...
... Concentrator, the SPD series takes the 'Classic' ... twist., The SPD121P SpeedVac comes equipped with ... runs; preventing samples from freezing; and allowing ... end-users preset level., Standard features on the ...
... are designed to create the ideal environment for ... to 99.9C) , Variable speed control (10 ... whether it be for washing or hybridizing ... temperature inside the chamber, ,is situated above a ...
... Express is the latest edition to the ... has an extra large diameter exhaust port ... display panel allows precise setting and control ... for handling large quantities and samples ...
Biology Products: